Addition by Subtraction: Disease Progression and the Value of Atrial Fibrillation Ablation

HomeCirculation: Arrhythmia and ElectrophysiologyVol. 16, No. 4Addition by Subtraction: Disease Progression and the Value of Atrial Fibrillation Ablation No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextAddition by Subtraction: Disease Progression and the Value of Atrial Fibrillation Ablation Matthew R. Reynolds Matthew R. ReynoldsMatthew R. Reynolds Correspondence to: Matthew R. Reynolds, MD, MSc, Lahey Hospital & Medical Center, 41 Mall Rd, Burlington, MA 01805. Email E-mail Address: [email protected] https://orcid.org/0000-0001-8675-8186 Division of Cardiology, Lahey Hospital & Medical Center, Burlington, MA. Baim Institute for Clinical Research, Boston, MA. Search for more papers by this author Originally published3 Apr 2023https://doi.org/10.1161/CIRCEP.123.011918Circulation: Arrhythmia and Electrophysiology. 2023;16This article is a commentary on the followingEconomic and Health Value of Delaying Atrial Fibrillation Progression Using Radiofrequency Catheter AblationFootnotesFor Sources of Funding and Disclosures, see page 190.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Matthew R. Reynolds, MD, MSc, Lahey Hospital & Medical Center, 41 Mall Rd, Burlington, MA 01805. Email matthew.r.[email protected]orgReferences1. Berman AE, Kabiri M, Wei T, Galvain T, Sha Q, Kuck K-H. Economic and health value of delaying atrial fibrillation progression using radiofrequency cathter ablation.Circ Arrhythm Electrophysiol. 2022; 16:e011237. doi: 10.1161/CIRCEP.122.011237LinkGoogle Scholar2. Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Geller L, Kalejs O, Neumann T, Davtyan K, On YK, Popov S, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).Europace. 2021; 23:362–369. doi: 10.1093/europace/euaa298CrossrefMedlineGoogle Scholar3. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation.J Am Coll Cardiol. 2006; 47:2513–2520. doi: 10.1016/j.jacc.2006.01.070CrossrefMedlineGoogle Scholar4. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation.Circ Arrhythm Electrophysiol. 2009; 2:362–369. doi: 10.1161/CIRCEP.108.837294LinkGoogle Scholar5. Aronsson M, Walfridsson H, Janzon M, Walfridsson U, Nielsen JC, Hansen PS, Johannessen A, Raatikainen P, Hindricks G, Kongstad O, et al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy.Europace. 2015; 17:48–55. doi: 10.1093/europace/euu188CrossrefMedlineGoogle Scholar6. Chew DS, Loring Z, Anand J, Fudim M, Lowenstern A, Rymer JA, Weimer KED, Atwater BD, DeVore AD, Exner DV, et al. Economic evaluation of catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction.Circ Cardiovasc Qual Outcomes. 2020; 13:e007094. doi: 10.1161/CIRCOUTCOMES.120.007094LinkGoogle Scholar7. Chew DS, Li Y, Cowper PA, Anstrom KJ, Piccini JP, Poole JE, Daniels MR, Monahan KH, Davidson-Ray L, Bahnson TD, et al; CABANA Investigators. Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial.Circulation. 2022; 146:535–547. doi: 10.1161/CIRCULATIONAHA.122.058575LinkGoogle Scholar8. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure.N Engl J Med. 2018; 378:417–427. doi: 10.1056/NEJMoa1707855CrossrefMedlineGoogle Scholar9. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, et al; ACC/AHA Task Force on Performance Measures. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.Circulation. 2014; 129:2329–2345. doi: 10.1161/CIR.0000000000000042LinkGoogle Scholar10. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, et al; CABANA Investigators. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial.JAMA. 2019; 321:1275–1285. doi: 10.1001/jama.2019.0692CrossrefMedlineGoogle Scholar11. Friedman DJ, Field ME, Rahman M, Goldstein L, Sha Q, Sidharth M, Khanna R, Piccini JP. Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation.Heart Rhythm O2. 2021; 2:28–36. doi: 10.1016/j.hroo.2020.12.017CrossrefMedlineGoogle Scholar12. Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, et al; EARLY-AF Investigators. Progression of atrial fibrillation after cryoablation or drug therapy.N Engl J Med. 2023; 388:105–116. doi: 10.1056/NEJMoa2212540CrossrefMedlineGoogle Scholar13. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, et al; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation.N Engl J Med. 2020; 383:1305–1316. doi: 10.1056/NEJMoa2019422CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesEconomic and Health Value of Delaying Atrial Fibrillation Progression Using Radiofrequency Catheter AblationAdam E. Berman, et al. Circulation: Arrhythmia and Electrophysiology. 2023;16 April 2023Vol 16, Issue 4 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.123.011918PMID: 37009736 Originally publishedApril 3, 2023 Keywordsquality of lifecost-effectiveness analysiscatheter ablationatrial fibrillationEditorialsPDF download Advertisement SubjectsAtrial FibrillationCatheter Ablation and Implantable Cardioverter-DefibrillatorCost-Effectiveness